ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/04/2026
Back to search
Official data from USPTO
APOLLO THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
APOLLO THERAPEUTICS
ST13
US500000090798637Class
5, 35, 36, 41, 42, 44
Filing
90798637
Registration
7172183
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
02/05/2026
Trademark type
Word
Nice classes
5, 35, 36, 41, 42, 44
Filing date
06/28/2021
Registration date
09/26/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/26/2023
Last transaction
02/05/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
24
Owner location
CAMBRIDGE, GB
Examiner
MAROTTA, GABRIELLE CHRISTINA
Law office
L30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
APOLLO THERAPEUTICS LIMITED
APOLLO THERAPEUTICS NO.2 LLP
A. L. (pessoa física)
Representatives
Benjamin Charkow MAURIEL KAPOUYTIAN WOODS LLP
Technical classification
Nice Classes
Class 5Class 35Class 36Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Therapeutic pharmaceuticals for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy in the nature of cells for medical usenamely autologous gene-engineered cells; medical preparations for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases
Class 35
Collection of data and management of data for business purposes in connection with clinical researchtestingtrial and development of pharmaceuticalstherapeutics and medical devices; computerized database management and data processing services in the field of medicalpharmaceutical and therapeutic treatment
Class 36
Financial sponsorship in the form of providing financial resources to non-hospital partnershipsassociations and companiesto aid in the researchdevelopmentproductionimportexportretailwholesalepromotioncommercial distribution and commercialisation of pharmaceuticaltherapeutic and medicinal products and preparations
Class 41
Education servicesproviding instruction in the field of pharmaceutical and therapeutic medical education; arranging and conducting of conferencescongressescoursesin particular in the fields of medicine and pharmaceuticals; publishing servicesthe publication of periodicalsbooksmagazinesarticles in the field of medicinepharmaceuticalstherapeutics; publication of periodicalsbooksmagazinesarticlesin particular in the fields of medicinepharmaceuticals and therapeutics
Class 42
Scientificmedical and pharmaceutical research and development services; clinical research in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; pharmaceutical drug development services; scientific investigations for medical purposes; medical laboratory services; laboratory research services related to pharmaceuticals; advisory services relating to medical and pharmaceutical science research in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; research and development of pharmaceutical preparations
Class 44
Non-emergency and non-clinical medical and pharmaceutical consulting services related to the use of pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines; non-emergency medical analysis services for diagnostic and treatment purposes related to the use of pharmaceutical preparationsnamely biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccinesprovided by medical laboratories; medical analysis and examination services related to the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseasesprovided by medical laboratories; medical treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases; advisory services relating to medical and pharmaceutical sciencemedical advisory services and pharmaceutical advisory services in the field of the use of biologicsbiosimilarssmall moleculesgene-engineered cell therapy and vaccines for the treatment of cardiovascular diseasesblood disordersrespiratory diseasesasthmacentral nervous system disorderscancer and tumorsdiseases and disorders of the autoimmune systemallergiesrenal transplanthypertensionchronic kidney diseasemetabolic diseases
Publications
History of USPTO decisions and trademark events.
41 publications found
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/26/2025
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/05/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/26/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
09/26/2023
DP1B
1(B) BASIS DELETED; PROCEED TO REGISTRATION
08/21/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
08/21/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/10/2023
D1BR
TEAS DELETE 1(B) BASIS RECEIVED
07/10/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/11/2023
PUBO
PUBLISHED FOR OPPOSITION
04/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/22/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/03/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
03/01/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/01/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
03/01/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/21/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/21/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/06/2023
GNRT
NON-FINAL ACTION E-MAILED
01/06/2023
CNRT
NON-FINAL ACTION WRITTEN
01/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/09/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/09/2022
DOCK
ASSIGNED TO EXAMINER
08/30/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/07/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
06/07/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/07/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/07/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/02/2022
GNRT
NON-FINAL ACTION E-MAILED
06/02/2022
CNRT
NON-FINAL ACTION WRITTEN
06/02/2022
DOCK
ASSIGNED TO EXAMINER
03/18/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/10/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/06/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/06/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/06/2021
NWAP
NEW APPLICATION ENTERED
07/01/2021
Continuous trademark protection
Get notified about every new filing that threatens APOLLO THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.